OGN
Organon & Co.
September 16, 2026 · pre-market
- Rarity
- 3.17
- Peak move
- −1.46%
- Float cap
- $3.5B
Organon & Co. is a global healthcare company delivering medicines and solutions in women's health and general medicines, including biosimilars and established brands. Its portfolio spans contraception, fertility, immunology, oncology, and more, with a focus on health needs that disproportionately affect women. Products reach over 140 countries through wholesalers, retailers, hospitals, government agencies, and managed care providers.
Where do you see this going?
no votes yetVoting closed at 4:00 PM ET.
What we found
1 event · 0 from SEC or newswire · 0 timed with the moveregulatory_approvalThe US FDA accepted for review a supplemental New Drug Application for MIUDELLA, a hormone-free copper IUD licensed to Organon, seeking to extend its approved duration of use from three to six years, with PDUFA action expected in Q2 2027 and a launch anticipated in late 2026.